Compare Commvault Systems Inc (CVLT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Recursion Pharmaceuticals Inc — how do they compare? Commvault Systems Inc trades at $151.12 (market cap $6.25B), while Recursion Pharmaceuticals Inc trades at $4.1 (market cap $2.14B). The key difference: Commvault Systems Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CVLT | RXRX | |
|---|---|---|
Market Cap | $6.25B | $2.14B |
Volume | 632,727 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $176.52 | $6.79 |
52-Week Low | $75.18 | $2.84 |
Typical Hold Time | 17 Days | 22 Days |
Enterprise Value | $6.24B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.74, up 0.31% with strong bullish technical momentum. The stock shows robust earnings performance, beating estimates for three consecutive quarters, with Q3 2026 results pending. Recent business developments include AWS Data Competency achievement and expanded FedRAMP authorization, positioning the company for growth in AI-driven resilience markets.
The outlook remains positive with 54.5% analyst buy ratings and a $156.55 consensus target, though high valuation multiples and declining profit margins warrant caution. Key risks include competitive pressures in cybersecurity and execution challenges in maintaining growth momentum amid expanding AI capabilities.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
